PDF(Pubmed)
Abstract：
Mycobacterium abscessus infections are increasing worldwide necessitating the development of new antibiotics and treatment regimens. The utility of third-generation tetracycline antibiotics was reestablished; their anti-M. abscessus activity needs further study. The activities of omadacycline (OMC), eravacycline (ERC), tigecycline (TGC), and sarecycline (SAC) were tested against two reference strains and 193 clinical M. abscessus isolates at different temperatures (30°C and 37°C). The minimum bactericidal concentrations (MBCs) of the four drugs were determined to distinguish between their bactericidal and bacteriostatic activities. The MICs of OMC, ERC, and TGC for the reference strains and clinical isolates were summarized and compared. OMC, ERC, and TGC exhibited a high level of bacteriostatic activity against M. abscessus. The MICs of OMC and ERC for M. abscess remained stable, while the MICs of TGC for the isolates/strains increased with increasing temperature. Notably, the MICs of OMC for M. abscessus isolates obtained in the United States are lower than for those obtained in China. IMPORTANCE The antimicrobial activities of four third-generation tetracycline-class drugs, omadacycline (OMC), eravacycline (ERC), tigecycline (TGC), and sarecycline (SAC), were determined for 193 M. abscessus isolates. The activities of the four drugs at two different temperatures (30°C and 37°C) were also tested. OMC, ERC, and TGC exhibited significant activity against M. abscessus. The anti-M. abscessus activity of TGC increased when the temperature was increased from 30°C to 37°C; the activities of OMC and ERC, on the other hand, remained the same. We found that in vitro MICs of OMC against Chinese and American isolates were distinct. Evaluations in in vivo models of M. abscessus disease or in the clinical setting will provide more accurate insight into potency of OMC against distinct isolates.
摘要：
脓肿分枝杆菌感染正在全球范围内增加，因此需要开发新的抗生素和治疗方案。重新建立了第三代四环素类抗生素的效用；他们的抗M。脓肿活动有待进一步研究。奥马环素（OMC）的活动，埃拉环素（ERC），替加环素（TGC），在不同温度（30°C和37°C）下，对两种参考菌株和193种临床脓肿分枝杆菌进行了测试。确定四种药物的最低杀菌浓度（MBC），以区分其杀菌和抑菌活性。OMC的中等收入国家，ERC,对参考菌株和临床分离株进行了总结和比较。OMC,ERC,和TGC对脓肿分枝杆菌表现出高水平的抑菌活性。OMC和ERC对M.脓肿的MIC保持稳定，而TGC对分离株/菌株的MIC随温度升高而增加。值得注意的是,在美国获得的脓肿分枝杆菌分离株的OMC的MIC低于在中国获得的。重要性四种第三代四环素类药物的抗菌活性，omadacycline(OMC),埃拉环素（ERC），替加环素（TGC），和sareccine(SAC)，对193株脓肿分枝杆菌进行了测定。还测试了四种药物在两种不同温度(30°C和37°C)下的活性。OMC,ERC,TGC对脓肿分枝杆菌表现出显著的活性。反M当温度从30°C升高到37°C时，TGC的脓肿活性增加；OMC和ERC的活性，另一方面,保持不变。我们发现OMC对中国和美国分离株的体外MIC是不同的。在脓肿分枝杆菌病的体内模型中或在临床环境中的评估将提供对OMC针对不同分离物的效力的更准确的了解。
